Our lead VDA product
Innovative therapeutic approach
A unique dual mechanism of action
Our lead VDA product is OXi4503, which is in a Phase 1b clinical trial in relapsed/refractory acute myeloid leukemia. OXi4503 has a unique dual mechanism of action that disrupts the shape of tumor bone marrow endothelial cells (BMECs) through reversible binding to tubulin at the colchicine binding site, downregulating intercellular adhesion molecules. This causes alterations to the endothelial cell shape, releasing quiescent adherent tumor cells from BMECs and activating the cell cycle, making the tumor cells vulnerable to chemotherapy. OXi4503 also directly kills tumor cells via myeloperoxidase activation of a fluorquinone cytotoxic mediator.